Go Ito and Tomohiro Muto were hunched over lab data in Tokyo when they uncovered a quiet revolution happening inside the inflamed colon — one that could rewrite how we understand ulcerative colitis. For years, the appearance of Paneth cells in the colon, a phenomenon called Paneth cell metaplasia (PCM), was seen as a troubling sign of chronic damage. But their research at the Institute of Science Tokyo reveals that this cellular shift may not be a symptom of harm, but a survival strategy. In a study published in Nature Communications on March 28, 2026, the team shows that PCM is triggered by inflammation itself — specifically through IL-22 signaling — and that these transformed cells produce REG3A, a protein with a surprising dual role: fighting microbes and healing the gut lining.
This discovery matters because ulcerative colitis affects millions worldwide, and treatment has long focused on suppressing inflammation. But what if the body is already trying to fix itself? The researchers analyzed endoscopic biopsies from UC patients and found that PCM was more common in the left colon and increased with disease duration, tightly linked to ongoing microscopic inflammation. Crucially, metaplastic Paneth cells showed strong expression of REG3A and genes activated by IL-22, a cytokine released by immune cells during inflammation. Far from being a passive marker, PCM appears to be an active repair mechanism — the gut’s way of patching up its damaged mucosa.
Mouse models reinforced the findings: animals lacking Reg3a in intestinal epithelial cells healed significantly slower from both acute and chronic colitis, confirming REG3A’s role in tissue regeneration. While mice don’t fully replicate human PCM, the conservation of Reg3a’s function across species underscores its biological importance. Yet the researchers urge caution. Because PCM drives epithelial cell growth, its persistence could raise the risk of inflammation-associated colorectal cancer — a known complication in long-term UC.
"When PCM is detected, clinicians should consider more frequent surveillance and intensified treatment, even in patients who appear to be in endoscopic remission," says Ito. This means PCM could serve a dual purpose: as a biomarker for hidden disease activity and as a guide for personalized monitoring. Beyond diagnostics, the findings open the door to new therapies that harness REG3A’s healing power without fueling cancer risk. In an era where precision medicine is reshaping care, this work reminds us that sometimes, the body’s most puzzling responses are its most protective. The gut, it seems, is not just inflamed — it’s fighting back.